Cyclerion Therapeutics Inc (CYCN)
2.84
-0.12
(-3.89%)
USD |
NASDAQ |
May 06, 16:00
Cyclerion Therapeutics Max Drawdown (5Y): 99.58% for April 30, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| April 30, 2024 | 99.58% |
| March 31, 2024 | 99.58% |
| February 29, 2024 | 99.58% |
| January 31, 2024 | 99.58% |
| December 31, 2023 | 99.58% |
| November 30, 2023 | 99.58% |
| October 31, 2023 | 99.43% |
| September 30, 2023 | 99.39% |
| August 31, 2023 | 99.39% |
| July 31, 2023 | 99.39% |
| June 30, 2023 | 99.16% |
| May 31, 2023 | 99.16% |
| April 30, 2023 | 98.80% |
| March 31, 2023 | 98.47% |
| February 28, 2023 | 98.47% |
| January 31, 2023 | 98.47% |
| December 31, 2022 | 98.47% |
| November 30, 2022 | 98.47% |
| October 31, 2022 | 98.47% |
| September 30, 2022 | 97.94% |
| August 31, 2022 | 97.94% |
| July 31, 2022 | 97.94% |
| June 30, 2022 | 97.94% |
| May 31, 2022 | 97.68% |
| April 30, 2022 | 96.78% |
| Date | Value |
|---|---|
| March 31, 2022 | 95.79% |
| February 28, 2022 | 95.79% |
| January 31, 2022 | 95.32% |
| December 31, 2021 | 93.17% |
| November 30, 2021 | 92.12% |
| October 31, 2021 | 92.12% |
| September 30, 2021 | 92.12% |
| August 31, 2021 | 92.12% |
| July 31, 2021 | 92.12% |
| June 30, 2021 | 92.12% |
| May 31, 2021 | 92.12% |
| April 30, 2021 | 92.12% |
| March 31, 2021 | 92.12% |
| February 28, 2021 | 92.12% |
| January 31, 2021 | 92.12% |
| December 31, 2020 | 92.12% |
| November 30, 2020 | 92.12% |
| October 31, 2020 | 92.12% |
| September 30, 2020 | 92.12% |
| August 31, 2020 | 92.12% |
| July 31, 2020 | 92.12% |
| June 30, 2020 | 92.12% |
| May 31, 2020 | 92.12% |
| April 30, 2020 | 92.12% |
| March 31, 2020 | 92.12% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
41.18%
Minimum
May 2019
99.58%
Maximum
Nov 2023
92.16%
Average
92.12%
Median
Nov 2019
Max Drawdown (5Y) Benchmarks
| Eli Lilly and Co | 22.48% |
| iBio Inc | 99.97% |
| AbbVie Inc | 45.08% |
| Agile Therapeutics Inc | 100.00% |
| NovaBay Pharmaceuticals Inc | 99.91% |